文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

寡进展性去势抵抗性前列腺癌的进展灶导向治疗:进展灶定位是预后因素

Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer: Localization of the Progressive Site as a Prognostic Factor.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-06-12

本研究纳入2014至2018年间考虑更换抗癌治疗且接受全身弥散加权磁共振成像的101例去势抵抗性前列腺癌(CRPC)患者,推荐对寡进展性CRPC(OP-CRPC)行进展灶导向治疗(PSDT)并继续原全身治疗。16例(70%)PSA下降≥50%,中位PSA进展时间8.7个月,进展灶位于盆腔内是PSA进展时间的显著预测因素。

要点

  • PSDT可使70%的OP-CRPC患者PSA下降≥50%,中位PSA进展时间8.7个月。
  • 盆腔内进展灶患者PSA下降≥50%比例达89%,显著高于非盆腔内进展灶的0%。
  • 盆腔内进展灶患者中位PSA进展时间10.1个月,显著长于非盆腔内进展灶的4.8个月。

核心结论

  • PSDT可作为OP-CRPC的有效治疗选择,进展灶定位是PSA良好应答的重要因素。

研究设计与样本

  • 本研究队列为2014至2018年间考虑更换抗癌治疗并接受全身弥散加权磁共振成像的101例CRPC患者。

主要发现

  • 接受PSDT患者的中位PSA为7.8 ng/mL,放疗靶区为前列腺/盆腔淋巴结(n=7)、骨(n=15)或两者(n=1)。
  • 16例(70%)PSA下降≥50%,中位PSA进展时间8.7个月。

临床怎么用

  • 对OP-CRPC可考虑在继续原全身治疗基础上联合放疗PSDT。
  • 进展灶位于盆腔内的OP-CRPC患者可能从PSDT中获得更好的PSA应答和更长的PSA进展时间。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Locoregional therapy for oligometastatic prostate cancer has generated great interest. However, its benefit for castration-resistant prostate cancer (CRPC) has not been fully demonstrated. Our objective was to evaluate the treatment outcome of progressive site-directed therapy (PSDT) for oligoprogressive CRPC (OP-CRPC). METHODS AND MATERIALS: This study cohort consisted of 101 patients with CRPC who underwent whole-body diffusion-weighted magnetic resonance imaging between 2014 and 2018, when a new line of anticancer therapy was being considered. For OP-CRPC, PSDT with radiation therapy and unchanged continuation of systemic therapy were recommended. RESULTS: Thirty-eight patients received a diagnosis of OP-CRPC, and 23 (61%) underwent PSDT at a median prostate-specific antigen (PSA) level of 7.8 ng/mL. The regional radiation therapy targets were the prostate/pelvic lymph nodes (n = 7), bone (n = 15), or both (n = 1). A decrease in PSA levels of at least 50% in response to PSDT (50% PSA decline) was observed in 16 cases (70%); the median time to PSA progression was 8.7 months. Intrapelvic localization of progressive lesions was a significant predictor of time to PSA progression (hazard ratio, 6.6; P = .007) as well as volumes of abnormal signal intensity on whole-body diffusion-weighted magnetic resonance imaging (hazard ratio, 0.5; P = .045). A 50% PSA decline was achieved in 16 of the 18 patients with intrapelvic OP-CRPC (89%) and in none of the 5 patients with non-intrapelvic OP-CRPC (P < .001). Intrapelvic OP-CRPC had a significantly longer time to PSA progression than non-intrapelvic OP-CRPC (10.1 vs 4.8 months, P = .0014). CONCLUSIONS: PSDT can be an effective treatment option for OP-CRPC. Progressive site localization was an important factor in good PSA response.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Yoshida S, Takahara T, Arita Y, et al. Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer: Localization of the Progressive Site as a Prognostic Factor. Int J Radiat Oncol Biol Phys. 2019. PMID: 31201896. doi:10.1016/j.ijrobp.2019.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。